Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED KINGDOM: Achieving SVR Reduces Hep C Treatment Costs


Clinical Advisor (02.17.2014)

The Clinical Advisor reported on a study of treatment costs for patients with hepatitis C virus (HCV) genotype 1 infection. William L. Irving of the University of Nottingham in the United Kingdom and colleagues determined use of healthcare services and related costs for 193 patients treated for a minimum of two months with pegylated interferon and ribavirin for HCV genotype-1 infection. The researchers reviewed data from the National Health Service Payment by Results database and the British National Formulary. They followed up on patients with no detectable HCV levels in their blood (sustained virologic response [SVR]) for an average of 3.5 years and those who did not achieve SVR for 4.9 years. Patients with SVR did not progress to liver disease while 7.4 percent of non-SVR patients developed chronic hepatitis and later cirrhosis and 4.9 percent developed decompensated liver disease. During follow-up, researchers reported a 13-fold cost increase among non-SVR patients and a 56-fold increase for those who were retreated. The researchers concluded that patient achievement of SVR had a significant effect on health service use and cost. The full report, “The Cost of Treatment Failure: Resource Use and Costs Incurred by Hepatitis C Virus Genotype 1-Infected Patients Who Do or Do Not Achieve Sustained Virological Response to Therapy,” was published in the journal of Viral Hepatitis (2014; 21(3):208–215).


Copyright © 2014 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in February 19, 2014. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.